Electrical impedance myography as a biomarker of inclusion body myositis: A cross-sectional study

• Published in: Clinical neurophysiology Vol. 131; no. 2; pp. 368 - 371
• Main Authors: Roy, Bhaskar, Rutkove, Seward B., Nowak, Richard J.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.02.2020
• Subjects: Biomarker; EIM; IBM; Outcome measures; EIM; Outcome measures; Biomarker; IBM
• ISSN: 1388-2457; 1872-8952
• DOI: 10.1016/j.clinph.2019.10.030

•Electrical impedance myography (EIM) detects changes in muscle in inclusion body myositis (IBM).•EIM parameters strongly correlate with clinical outcome measures of IBM.•EIM can potentially be used as a biomarker of IBM. To assess the value of electrical impedance myography (EIM) in inclusion body myositis (IBM). Patients with clinically defined IBM and healthy controls (HC) of similar age group were recruited. Each participant underwent manual muscle testing (MMT), 6-min walk test (6MWT), handgrip dynamometry, and IBM-functional rating scale assessment (IBM-FRS). EIM measurements were obtained from bilateral deltoid, biceps, forearm-flexors, quadriceps, tibialis anterior, and medial gastrocnemius. Fourteen IBM patients and 12 HCs with mean age 68.6 ± 6 and 67.4 ± 5.4 years were included in the final analysis. Averaged phase value at 50 kHz (EIM50) and ratio of phase value at 50 kHz/200 kHz (EIMPR) from six-muscles were significantly lower in IBM patients when compared to HC (5.23 ± 1.34 vs 7.88 ± 1.9, p-value 0.002, and 0.55 ± 0.09 vs. 0.68 ± 0.09, p-value 0.004, respectively). A strong correlation was noted between IBM-FRS, 6MWT, disease-duration and the averaged value of EIM50 and EIMPR in the IBM patients (Spearman |rho|>0.7, p-values < 0.01). EIM can differentiate between IBM patients and HCs and EIM parameters correlate with clinical outcome measures. EIM may be a potential objective biomarker for IBM. A longitudinal validation study is warranted.